Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
Advertisement
Articles by Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.
Advertisement
Latest Updated Articles
Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate CancerPublished: September 30th 2020 | Updated:
Dr. McDermott on Preventing Recurrence of High-Risk Prostate CancerPublished: October 21st 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5